DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Other: Exercise Intervention

First Posted Date: 2017-03-03

Last Posted Date: 2021-09-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT03070145

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors
Head & Neck Cancer
Lung Cancer Squamous Cell
Pancreatic Cancer

Interventions: Drug: Palbociclib
Drug: Gedatolisib

First Posted Date: 2017-02-27

Last Posted Date: 2025-03-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 96

Registration Number: NCT03065062

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

Active, not recruiting

Conditions: Pancreatic Cancer

First Posted Date: 2017-02-23

Last Posted Date: 2025-03-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 271

Registration Number: NCT03060720

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Phase 2

Active, not recruiting

Conditions: Richter Syndrome

Interventions: Drug: Venetoclax
Other: DA-EPOCH-R
Other: R-CHOP

First Posted Date: 2017-02-16

Last Posted Date: 2025-01-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 69

Registration Number: NCT03054896

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Eribulin Mesylate
Drug: Pembrolizumab

First Posted Date: 2017-02-14

Last Posted Date: 2024-03-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 90

Registration Number: NCT03051659

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Pembrolizumab
Radiation: Palliative radiotherapy

First Posted Date: 2017-02-14

Last Posted Date: 2021-04-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT03051672

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: T-DM1
Drug: Pembrolizumab

First Posted Date: 2017-01-26

Last Posted Date: 2025-01-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03032107

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

The HOPE Trial and the SMART Study

Not Applicable

Active, not recruiting

Conditions: Gynecologic Cancer

Interventions: Other: HOPE App
Device: Fitbit Zip
Other: SMART Study Intervention
Other: Standard of Care
Device: Fitbit Charge 2

First Posted Date: 2017-01-16

Last Posted Date: 2024-05-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 102

Registration Number: NCT03022032

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Interventions: Drug: Pegaspargase
Drug: Erwinia asparaginase
Drug: Cyclophosphamide
Drug: DEXAMETHASONE
Drug: CYTARABINE
Drug: DASATINIB
Drug: LEUCOVORIN CALCIUM
Drug: Dexrazoxane
Drug: Doxorubicin
Drug: MERCAPTOPURINE
Drug: METHOTREXATE
Drug: ETOPOSIDE
Drug: HYDROCORTISONE
Drug: Vincristine
Drug: NELARABINE

First Posted Date: 2017-01-13

Last Posted Date: 2025-01-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 560

Registration Number: NCT03020030

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦
Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada

and more 6 locations

CISPLATIN + AZD-1775 In Breast Cancer

Phase 2

Completed

Conditions: Triple-negative Metastatic Breast Cancer

Interventions: Drug: Cisplatin
Drug: AZD1775

First Posted Date: 2017-01-06

Last Posted Date: 2021-11-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 34

Registration Number: NCT03012477

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy